Curanex Pharmaceuticals Inc (CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative...

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage...

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of...

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New...

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader...

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum...

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and...

Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board

New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies...

Curanex Forms World Class Scientific Advisory Board

Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York...

Curanex Provides Operational Update on Key Regulatory Milestones

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York...

Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex”...

Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters

Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex”...

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities